Trial Profile

Randomized phase II study of the combination of oral vinorelbine with capecitabine versus gemcitabine in combination with paclitaxel versus gemcitabine in combination with docetaxel as first line chemotherapy in patients with metastatic breast cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 25 Oct 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vinorelbine (Primary) ; Capecitabine; Docetaxel; Gemcitabine; Paclitaxel
Indications Advanced breast cancer; HER2 negative breast cancer
Focus Therapeutic Use
Acronyms NORCAP

16 Aug 2014 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.
30 May 2014 Primary endpoint 'Disease-control-rate' has been met.
30 May 2014 Final results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com